NASDAQ:DRRX - DURECT Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.97 +0.09 (+4.79 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$1.97
Today's Range$1.86 - $2.10
52-Week Range$0.75 - $2.55
Volume1.83 million shs
Average Volume583,299 shs
Market Capitalization$304.01 million
P/E Ratio-65.67
Dividend YieldN/A
Beta1.04

About DURECT (NASDAQ:DRRX)

DURECT logoDURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials in their products for pharmaceutical and medical devices under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in clinical development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's advanced oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including REMOXY ER, an investigational extended release pain relief drug based on ORADUR technology; and POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has collaboration agreements with Sandoz AG; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Zogenix, Inc.; and Pain Therapeutics, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.

Receive DRRX News and Ratings via Email

Sign-up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DRRX
CUSIPN/A
Phone408-777-1417

Debt

Debt-to-Equity Ratio0.50
Current Ratio4.61
Quick Ratio4.32

Price-To-Earnings

Trailing P/E Ratio-65.67
Forward P/E Ratio-8.57
P/E GrowthN/A

Sales & Book Value

Annual Sales$49.17 million
Price / Sales6.48
Cash FlowN/A
Price / CashN/A
Book Value$0.19 per share
Price / Book10.37

Profitability

EPS (Most Recent Fiscal Year)($0.03)
Net Income$-3,690,000.00
Net Margins-8.06%
Return on Equity-25.82%
Return on Assets-7.04%

Miscellaneous

Employees93
Outstanding Shares161,710,000

DURECT (NASDAQ:DRRX) Frequently Asked Questions

What is DURECT's stock symbol?

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) issued its earnings results on Friday, May, 11th. The specialty pharmaceutical company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01. The specialty pharmaceutical company earned $3.49 million during the quarter, compared to the consensus estimate of $4.20 million. DURECT had a negative net margin of 8.06% and a negative return on equity of 25.82%. View DURECT's Earnings History.

When is DURECT's next earnings date?

DURECT is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for DURECT.

What price target have analysts set for DRRX?

3 brokers have issued 12 month price targets for DURECT's stock. Their forecasts range from $2.00 to $3.50. On average, they expect DURECT's share price to reach $2.8333 in the next year. View Analyst Ratings for DURECT.

Are investors shorting DURECT?

DURECT saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 2,055,206 shares, an increase of 32.1% from the March 30th total of 1,555,657 shares. Based on an average trading volume of 890,814 shares, the short-interest ratio is currently 2.3 days. Currently, 1.4% of the company's stock are short sold.

Who are some of DURECT's key competitors?

Who are DURECT's key executives?

DURECT's management team includes the folowing people:
  • Dr. Felix Theeuwes, Co-Founder, Chairman & Distinguished Scientist (Age 80)
  • Dr. James E. Brown, Co-Founder, CEO, Pres & Director (Age 61)
  • Mr. Matthew J. Hogan, Principal Accounting Officer, CFO & Sec. (Age 58)
  • Ms. Judy R. Joice, Sr. VP of Operations & Corp. Quality Assurance (Age 61)
  • Mr. Michael H. Arenberg J.D., M.B.A., Sr. VP of Corp. & Bus. Devel.

Has DURECT been receiving favorable news coverage?

News coverage about DRRX stock has trended somewhat positive recently, according to Accern. Accern scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. DURECT earned a daily sentiment score of 0.06 on Accern's scale. They also assigned media headlines about the specialty pharmaceutical company an impact score of 44.36 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are DURECT's major shareholders?

DURECT's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.10%), Northern Trust Corp (1.00%), Asymmetry Capital Management L.P. (0.47%), Millennium Management LLC (0.42%), Algert Global LLC (0.31%) and Mackay Shields LLC (0.11%). View Institutional Ownership Trends for DURECT.

Which institutional investors are selling DURECT stock?

DRRX stock was sold by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P. and A.R.T. Advisors LLC. View Insider Buying and Selling for DURECT.

Which institutional investors are buying DURECT stock?

DRRX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Algert Global LLC, Mackay Shields LLC, Engineers Gate Manager LP, MetLife Investment Advisors LLC, Cubist Systematic Strategies LLC and Northern Trust Corp. View Insider Buying and Selling for DURECT.

How do I buy shares of DURECT?

Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is DURECT's stock price today?

One share of DRRX stock can currently be purchased for approximately $1.97.

How big of a company is DURECT?

DURECT has a market capitalization of $304.01 million and generates $49.17 million in revenue each year. The specialty pharmaceutical company earns $-3,690,000.00 in net income (profit) each year or ($0.03) on an earnings per share basis. DURECT employs 93 workers across the globe.

How can I contact DURECT?

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417.


MarketBeat Community Rating for DURECT (DRRX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  161 (Vote Outperform)
Underperform Votes:  101 (Vote Underperform)
Total Votes:  262
MarketBeat's community ratings are surveys of what our community members think about DURECT and other stocks. Vote "Outperform" if you believe DRRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

DURECT (NASDAQ:DRRX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for DURECT in the last 12 months. Their average twelve-month price target is $2.8333, suggesting that the stock has a possible upside of 43.82%. The high price target for DRRX is $3.50 and the low price target for DRRX is $2.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldHold
Consensus Rating Score: 2.672.672.332.33
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.8333$2.8333$2.6667$2.6667
Price Target Upside: 43.82% upside88.89% upside234.46% upside234.46% upside

DURECT (NASDAQ:DRRX) Consensus Price Target History

Price Target History for DURECT (NASDAQ:DRRX)

DURECT (NASDAQ:DRRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/6/2018HC WainwrightUpgradeNeutral ➝ Buy$1.50 ➝ $3.50HighView Rating Details
10/20/2017LaidlawLower Price TargetBuy ➝ Buy$3.00 ➝ $2.00N/AView Rating Details
10/20/2017Stifel NicolausDowngradeBuy ➝ HoldN/AView Rating Details
9/27/2016Rodman & RenshawReiterated RatingBuy$4.00 ➝ $3.50N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

DURECT (NASDAQ:DRRX) Earnings History and Estimates Chart

Earnings by Quarter for DURECT (NASDAQ:DRRX)

DURECT (NASDAQ:DRRX) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.23 EPS
Next Year EPS Consensus Estimate: $-0.24 EPS

DURECT (NASDAQ DRRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2018        
5/11/2018Q1 2018($0.06)($0.05)$4.20 million$3.49 millionViewListenView Earnings Details
3/1/2018Q4 2017($0.06)$0.05$4.60 million$19.54 millionViewListenView Earnings Details
11/1/2017Q3 2017($0.05)$0.04$5.09 million$20.75 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.05)($0.07)$5.17 million$4.32 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.06)($0.06)$3.60 million$4.57 millionViewN/AView Earnings Details
3/14/2017Q4 2016($0.06)($0.06)$3.03 million$3.52 millionViewN/AView Earnings Details
10/31/2016Q316($0.07)($0.06)$3.72 million$37.00 millionViewListenView Earnings Details
8/1/2016Q216($0.06)($0.07)$3.69 million$3.20 millionViewListenView Earnings Details
5/5/2016Q116($0.06)($0.06)$4.09 million$3.60 millionViewListenView Earnings Details
2/29/2016Q415($0.06)($0.05)$4.83 million$5.20 millionViewListenView Earnings Details
11/2/2015Q315($0.05)($0.05)$5.08 million$4.70 millionViewListenView Earnings Details
8/3/2015Q215($0.06)($0.05)$5.01 million$4.40 millionViewListenView Earnings Details
4/30/2015Q115($0.06)($0.04)$4.82 million$4.77 millionViewListenView Earnings Details
3/2/2015Q414($0.05)($0.05)$4.32 million$4.30 millionViewListenView Earnings Details
11/3/2014Q3($0.05)($0.06)$4.10 million$4.26 millionViewListenView Earnings Details
8/7/2014Q2($0.05)($0.05)$3.90 million$4.58 millionViewListenView Earnings Details
5/1/2014Q1($0.05)($0.03)$4.12 million$6.30 millionViewListenView Earnings Details
2/27/2014Q4($0.06)($0.05)$2.79 million$4.30 millionViewListenView Earnings Details
11/4/2013Q3 2013($0.06)($0.06)$3.57 million$2.97 millionViewN/AView Earnings Details
8/5/2013Q2 2013($0.05)($0.05)$3.42 million$3.92 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.06)($0.05)$3.78 million$4.15 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.06)($0.06)ViewN/AView Earnings Details
11/5/2012Q3 2012($0.05)($0.05)ViewN/AView Earnings Details
8/6/2012Q2 2012($0.04)($0.05)ViewN/AView Earnings Details
5/3/2012Q1 2012($0.07)$0.35ViewN/AView Earnings Details
3/1/2012Q4 2011($0.08)($0.02)ViewN/AView Earnings Details
11/3/2011Q3 2011($0.05)($0.06)ViewN/AView Earnings Details
8/4/2011Q2 2011($0.07)($0.06)ViewN/AView Earnings Details
5/5/2011Q1 2011($0.06)($0.07)ViewN/AView Earnings Details
3/2/2011Q4 2010($0.06)($0.06)ViewN/AView Earnings Details
11/3/2010Q3 2010($0.06)($0.05)ViewN/AView Earnings Details
8/4/2010Q2 2010($0.08)($0.07)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.09)($0.08)ViewN/AView Earnings Details
2/24/2010Q4 2009($0.09)($0.10)ViewN/AView Earnings Details
10/29/2009Q3 2009($0.09)($0.07)ViewN/AView Earnings Details
8/3/2009Q2 2009($0.10)($0.09)ViewN/AView Earnings Details
5/6/2009Q1 2009($0.08)($0.11)ViewN/AView Earnings Details
2/9/2009Q4 2008($0.10)($0.07)ViewN/AView Earnings Details
11/3/2008Q3 2008($0.09)($0.11)ViewN/AView Earnings Details
8/5/2008Q2 2008($0.10)($0.11)ViewN/AView Earnings Details
5/7/2008Q1 2008($0.10)($0.11)ViewN/AView Earnings Details
2/5/2008Q4 2007($0.10)($0.10)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

DURECT (NASDAQ:DRRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

DURECT (NASDAQ DRRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.70%
Institutional Ownership Percentage: 44.44%
Insider Trading History for DURECT (NASDAQ:DRRX)
Institutional Ownership by Quarter for DURECT (NASDAQ:DRRX)

DURECT (NASDAQ DRRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/3/2016April Fund L.P. 21Major ShareholderBuy95,000$1.16$110,200.00View SEC Filing  
9/26/2016April Fund L.P. 21Major ShareholderBuy2,500,000$1.15$2,875,000.00View SEC Filing  
4/26/2016April Fund L.P. 21Major ShareholderBuy5,500,000$1.25$6,875,000.00View SEC Filing  
4/26/2016Dave HoffmannDirectorBuy200,000$1.25$250,000.0025,000View SEC Filing  
4/26/2016Felix TheeuwesChairmanBuy160,000$1.25$200,000.00View SEC Filing  
3/14/2016Armand NeukermansDirectorBuy18,000$1.39$25,020.001,250View SEC Filing  
3/14/2016Felix TheeuwesChairmanBuy70,000$1.41$98,700.00View SEC Filing  
3/10/2016James E BrownCEOBuy20,000$1.33$26,600.001,764,530View SEC Filing  
1/11/2016April Fund Lp 21Major ShareholderBuy300,100$1.37$411,137.00View SEC Filing  
9/29/2015April Fund Ltd 21Major ShareholderBuy952,249$1.79$1,704,525.71View SEC Filing  
3/10/2015Simon X BenitoDirectorBuy40,000$1.81$72,400.00View SEC Filing  
3/9/2015Felix TheeuwesChairmanBuy225,600$1.65$372,240.00View SEC Filing  
3/6/2015Felix TheeuwesChairmanBuy380,000$1.57$596,600.00View SEC Filing  
11/21/2014Felix TheeuwesChairmanBuy72,700$1.00$72,700.00View SEC Filing  
11/20/2014Felix TheeuwesChairmanBuy136,015$0.92$125,133.80View SEC Filing  
11/8/2013Felix TheeuwesChairmanBuy714,285$1.40$999,999.00View SEC Filing  
9/10/2013Felix TheeuwesChairmanBuy75,000$1.20$90,000.00View SEC Filing  
9/9/2013Felix TheeuwesChairmanBuy25,000$1.15$28,750.00View SEC Filing  
6/4/2013James E BrownCEOBuy30,000$0.80$24,000.00View SEC Filing  
12/12/2012Jon S SaxeDirectorBuy15,000$0.91$13,650.00View SEC Filing  
11/14/2012Felix TheeuwesChairmanBuy100,000$1.01$101,000.00View SEC Filing  
8/28/2012Jon S SaxeDirectorBuy7,810$0.97$7,575.70View SEC Filing  
8/23/2012Jon S SaxeDirectorBuy5,000$1.00$5,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

DURECT (NASDAQ DRRX) News Headlines

Source:
DateHeadline
Durect Co. (DRRX) Expected to Post Quarterly Sales of $3.83 MillionDurect Co. (DRRX) Expected to Post Quarterly Sales of $3.83 Million
www.americanbankingnews.com - May 13 at 1:58 AM
 Brokerages Expect Durect Co. (DRRX) to Post -$0.06 EPS Brokerages Expect Durect Co. (DRRX) to Post -$0.06 EPS
www.americanbankingnews.com - May 11 at 9:19 PM
BRIEF-Durect Announces Amendment To Licensing Agreement With SandozBRIEF-Durect Announces Amendment To Licensing Agreement With Sandoz
www.reuters.com - May 10 at 8:30 AM
DURECT up 8% premarket on revised Posimir contract with SandozDURECT up 8% premarket on revised Posimir contract with Sandoz
seekingalpha.com - May 9 at 5:29 PM
Durect (DRRX) Cut to "Hold" at BidaskClubDurect (DRRX) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - May 8 at 10:22 AM
Want To Invest In DURECT Corporation (NASDAQ:DRRX)? Here’s How It Performed LatelyWant To Invest In DURECT Corporation (NASDAQ:DRRX)? Here’s How It Performed Lately
finance.yahoo.com - May 8 at 8:23 AM
Edited Transcript of DRRX earnings conference call or presentation 2-May-18 8:30pm GMTEdited Transcript of DRRX earnings conference call or presentation 2-May-18 8:30pm GMT
finance.yahoo.com - May 3 at 8:22 AM
Durect: 1Q Earnings SnapshotDurect: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 8:22 AM
Durect (DRRX) Issues  Earnings ResultsDurect (DRRX) Issues Earnings Results
www.americanbankingnews.com - May 2 at 10:46 PM
OncoSec Medical (ONCS) & Durect (DRRX) Critical AnalysisOncoSec Medical (ONCS) & Durect (DRRX) Critical Analysis
www.americanbankingnews.com - May 2 at 5:44 PM
DURECT Corporation Announces First Quarter 2018 Financial Results and Provides Corporate UpdateDURECT Corporation Announces First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 2 at 5:31 PM
Durect Co. (DRRX) Short Interest UpdateDurect Co. (DRRX) Short Interest Update
www.americanbankingnews.com - April 28 at 2:28 AM
Durect Co. (DRRX) Expected to Announce Quarterly Sales of $4.20 MillionDurect Co. (DRRX) Expected to Announce Quarterly Sales of $4.20 Million
www.americanbankingnews.com - April 26 at 3:50 AM
Durect (DRRX) to Release Quarterly Earnings on WednesdayDurect (DRRX) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 25 at 12:18 PM
Quotidian Technical Highlights on Selected Drug Makers Stocks -- Amarin, Apricus Biosciences, Depomed, and DURECTQuotidian Technical Highlights on Selected Drug Makers Stocks -- Amarin, Apricus Biosciences, Depomed, and DURECT
www.prnewswire.com - April 25 at 8:25 AM
DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic HepatitisDURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic Hepatitis
finance.yahoo.com - April 25 at 8:25 AM
DURECT Corporation Invites You to Join its First Quarter 2018 Earnings Conference CallDURECT Corporation Invites You to Join its First Quarter 2018 Earnings Conference Call
finance.yahoo.com - April 24 at 5:31 PM
 Brokerages Anticipate Durect Co. (DRRX) to Post -$0.06 EPS Brokerages Anticipate Durect Co. (DRRX) to Post -$0.06 EPS
www.americanbankingnews.com - April 24 at 11:11 AM
Durect (DRRX) Downgraded by BidaskClub to "Buy"Durect (DRRX) Downgraded by BidaskClub to "Buy"
www.americanbankingnews.com - April 20 at 11:39 AM
Durect (DRRX) Upgraded by Stifel Nicolaus to "Buy"Durect (DRRX) Upgraded by Stifel Nicolaus to "Buy"
www.americanbankingnews.com - April 18 at 9:10 PM
Zacks: Analysts Anticipate Durect Co. (DRRX) Will Post Quarterly Sales of $4.20 MillionZacks: Analysts Anticipate Durect Co. (DRRX) Will Post Quarterly Sales of $4.20 Million
www.americanbankingnews.com - April 9 at 2:54 AM
Durect (DRRX) Upgraded by ValuEngine to HoldDurect (DRRX) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - April 8 at 7:34 PM
Durect Co. (DRRX) Expected to Post Earnings of -$0.06 Per ShareDurect Co. (DRRX) Expected to Post Earnings of -$0.06 Per Share
www.americanbankingnews.com - April 7 at 1:22 PM
Analyzing Oramed Pharmaceuticals (ORMP) and Durect (DRRX)Analyzing Oramed Pharmaceuticals (ORMP) and Durect (DRRX)
www.americanbankingnews.com - April 4 at 3:21 PM
Durects (DRRX) "Hold" Rating Reaffirmed at HC WainwrightDurect's (DRRX) "Hold" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - April 2 at 8:20 AM
DURECT Corporation to Host Key Opinion Leader Call on Alcoholic HepatitisDURECT Corporation to Host Key Opinion Leader Call on Alcoholic Hepatitis
finance.yahoo.com - March 29 at 8:35 AM
DURECT Corporation: Upcoming Milestones And DUR-928 ProgressDURECT Corporation: Upcoming Milestones And DUR-928 Progress
seekingalpha.com - March 24 at 5:10 PM
$4.20 Million in Sales Expected for DURECT Co. (DRRX) This Quarter$4.20 Million in Sales Expected for DURECT Co. (DRRX) This Quarter
www.americanbankingnews.com - March 23 at 4:24 AM
DURECT Announces FDA Advisory Committee Meeting for REMOXY® ER - PR Newswire (press release)DURECT Announces FDA Advisory Committee Meeting for REMOXY® ER - PR Newswire (press release)
www.prnewswire.com - March 20 at 8:36 AM
DURECT Announces FDA Advisory Committee Meeting for REMOXY® ERDURECT Announces FDA Advisory Committee Meeting for REMOXY® ER
finance.yahoo.com - March 20 at 8:36 AM
DURECT (DRRX) Upgraded at ValuEngineDURECT (DRRX) Upgraded at ValuEngine
www.americanbankingnews.com - March 19 at 12:40 AM
Is DURECT Corporation (NASDAQ:DRRX) Undervalued?Is DURECT Corporation (NASDAQ:DRRX) Undervalued?
finance.yahoo.com - March 12 at 9:52 AM
DURECT (DRRX) Lifted to Buy at BidaskClubDURECT (DRRX) Lifted to Buy at BidaskClub
www.americanbankingnews.com - March 10 at 4:33 PM
DURECT (DRRX) Lifted to "Buy" at HC WainwrightDURECT (DRRX) Lifted to "Buy" at HC Wainwright
www.americanbankingnews.com - March 6 at 11:24 PM
HC Wainwright Upgrades Durect Corp (DRRX) to Buy - StreetInsider.comHC Wainwright Upgrades Durect Corp (DRRX) to Buy - StreetInsider.com
www.streetinsider.com - March 6 at 8:22 AM
DURECT (DRRX) Set to Announce Quarterly Earnings on MondayDURECT (DRRX) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - March 5 at 2:16 AM
Contrasting Proteon Therapeutics (PRTO) & DURECT (DRRX)Contrasting Proteon Therapeutics (PRTO) & DURECT (DRRX)
www.americanbankingnews.com - March 4 at 11:06 PM
Gagnon Securities LLC Trims Stake in DURECT Co. (DRRX)Gagnon Securities LLC Trims Stake in DURECT Co. (DRRX)
www.americanbankingnews.com - March 3 at 3:01 PM
DURECTs (DRRX) CEO James Brown on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaDURECT's (DRRX) CEO James Brown on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 2 at 8:25 AM
Durect tops 4Q revenue forecastsDurect tops 4Q revenue forecasts
finance.yahoo.com - March 2 at 8:24 AM
DURECT Corporation Announces Fourth Quarter and Full Year 2017 Financial Results and Update of ProgramsDURECT Corporation Announces Fourth Quarter and Full Year 2017 Financial Results and Update of Programs
finance.yahoo.com - March 1 at 5:46 PM
DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis (PSC) - PR Newswire (press release)DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis (PSC) - PR Newswire (press release)
www.prnewswire.com - February 28 at 8:25 AM
DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis (PSC)DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis (PSC)
finance.yahoo.com - February 26 at 8:24 AM
DURECT (DRRX) to Release Earnings on ThursdayDURECT (DRRX) to Release Earnings on Thursday
www.americanbankingnews.com - February 23 at 5:26 PM
DURECT Corporation Invites You to Join its Fourth Quarter 2017 Earnings Conference CallDURECT Corporation Invites You to Join its Fourth Quarter 2017 Earnings Conference Call
finance.yahoo.com - February 22 at 5:33 PM
DURECT Corporation to Host Key Opinion Leader Call on Treatment of Primary Sclerosing Cholangitis (PSC) - PR Newswire (press release)DURECT Corporation to Host Key Opinion Leader Call on Treatment of Primary Sclerosing Cholangitis (PSC) - PR Newswire (press release)
www.prnewswire.com - February 21 at 8:29 AM
DURECT Corporation to Host Key Opinion Leader Call on Treatment of Primary Sclerosing Cholangitis (PSC)DURECT Corporation to Host Key Opinion Leader Call on Treatment of Primary Sclerosing Cholangitis (PSC)
finance.yahoo.com - February 20 at 8:23 AM
DURECT Co. (DRRX) Expected to Post Quarterly Sales of $4.60 MillionDURECT Co. (DRRX) Expected to Post Quarterly Sales of $4.60 Million
www.americanbankingnews.com - February 17 at 6:24 AM
DURECT Announces Resubmission of REMOXY® ER New Drug Application by its licensee, Pain TherapeuticsDURECT Announces Resubmission of REMOXY® ER New Drug Application by its licensee, Pain Therapeutics
finance.yahoo.com - February 14 at 9:49 AM
DURECT (DRRX) & Adaptimmune Therapeutics (ADAP) Critical ContrastDURECT (DRRX) & Adaptimmune Therapeutics (ADAP) Critical Contrast
www.americanbankingnews.com - February 8 at 1:18 AM

SEC Filings

DURECT (NASDAQ:DRRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

DURECT (NASDAQ:DRRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

DURECT (NASDAQ DRRX) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.